SG11202011961YA - Dosing and effect of c5a antagonist with anca-associated vasculitis - Google Patents
Dosing and effect of c5a antagonist with anca-associated vasculitisInfo
- Publication number
- SG11202011961YA SG11202011961YA SG11202011961YA SG11202011961YA SG11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA
- Authority
- SG
- Singapore
- Prior art keywords
- anca
- antagonist
- dosing
- effect
- associated vasculitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862682013P | 2018-06-07 | 2018-06-07 | |
PCT/US2019/035758 WO2019236820A1 (en) | 2018-06-07 | 2019-06-06 | Dosing and effect of c5a antagonist with anca-associated vasculitis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011961YA true SG11202011961YA (en) | 2020-12-30 |
Family
ID=68764799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011961YA SG11202011961YA (en) | 2018-06-07 | 2019-06-06 | Dosing and effect of c5a antagonist with anca-associated vasculitis |
Country Status (14)
Country | Link |
---|---|
US (2) | US11191756B2 (en) |
EP (1) | EP3801519A4 (en) |
JP (1) | JP2021527062A (en) |
KR (1) | KR20210018906A (en) |
CN (1) | CN112423752A (en) |
AU (1) | AU2019282327A1 (en) |
BR (1) | BR112020024842A2 (en) |
CA (1) | CA3102403A1 (en) |
CL (1) | CL2020003171A1 (en) |
IL (1) | IL279188A (en) |
MA (1) | MA52808A (en) |
MX (1) | MX2020013166A (en) |
SG (1) | SG11202011961YA (en) |
WO (1) | WO2019236820A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
JP2023501789A (en) | 2019-11-08 | 2023-01-19 | ケモセントリックス,インコーポレイティド | Amorphous Form of Complement Component C5a Receptor |
CA3235574A1 (en) | 2019-11-08 | 2021-05-14 | Chemocentryx, Inc. | Salt forms of a complement component c5a receptor |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1739078A1 (en) * | 2005-05-30 | 2007-01-03 | Jerini AG | Antagonists of C5a-receptor |
JP2010513530A (en) | 2006-12-22 | 2010-04-30 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | C3A receptor modulator and method of use thereof |
US8268972B2 (en) * | 2008-02-20 | 2012-09-18 | G2 Inflammation Pty Ltd | Humanized anti-C5aR antibodies |
US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
WO2010075257A1 (en) * | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
PL2585064T3 (en) | 2010-06-24 | 2017-09-29 | Chemocentryx, Inc. | C5ar antagonists |
CN113121415A (en) | 2014-09-29 | 2021-07-16 | 凯莫森特里克斯股份有限公司 | Processes and intermediates for preparing C5aR antagonists |
ES2781980T3 (en) | 2015-04-17 | 2020-09-09 | Euroimmun Medizinische Labordiagnostika Ag | Procedure and diagnostic test for rapidly progressive glomerulonephritis in a subject |
MX2018011831A (en) | 2016-04-04 | 2019-02-13 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS. |
WO2019089534A1 (en) | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5aR INHIBITOR REDUCTION OF URINARY sCD163 |
-
2019
- 2019-06-06 MX MX2020013166A patent/MX2020013166A/en unknown
- 2019-06-06 MA MA052808A patent/MA52808A/en unknown
- 2019-06-06 EP EP19814841.3A patent/EP3801519A4/en active Pending
- 2019-06-06 CA CA3102403A patent/CA3102403A1/en active Pending
- 2019-06-06 US US16/433,487 patent/US11191756B2/en active Active
- 2019-06-06 WO PCT/US2019/035758 patent/WO2019236820A1/en active Search and Examination
- 2019-06-06 SG SG11202011961YA patent/SG11202011961YA/en unknown
- 2019-06-06 BR BR112020024842-8A patent/BR112020024842A2/en unknown
- 2019-06-06 KR KR1020217000253A patent/KR20210018906A/en unknown
- 2019-06-06 CN CN201980038855.4A patent/CN112423752A/en active Pending
- 2019-06-06 AU AU2019282327A patent/AU2019282327A1/en active Pending
- 2019-06-06 JP JP2020567973A patent/JP2021527062A/en active Pending
-
2020
- 2020-12-03 IL IL279188A patent/IL279188A/en unknown
- 2020-12-04 CL CL2020003171A patent/CL2020003171A1/en unknown
-
2021
- 2021-11-04 US US17/519,266 patent/US20220296576A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA52808A (en) | 2021-04-14 |
US11191756B2 (en) | 2021-12-07 |
KR20210018906A (en) | 2021-02-18 |
US20190374524A1 (en) | 2019-12-12 |
US20220296576A1 (en) | 2022-09-22 |
BR112020024842A2 (en) | 2021-03-02 |
CA3102403A1 (en) | 2019-12-12 |
AU2019282327A1 (en) | 2021-01-07 |
WO2019236820A1 (en) | 2019-12-12 |
EP3801519A1 (en) | 2021-04-14 |
IL279188A (en) | 2021-01-31 |
JP2021527062A (en) | 2021-10-11 |
CL2020003171A1 (en) | 2021-06-04 |
MX2020013166A (en) | 2021-03-29 |
CN112423752A (en) | 2021-02-26 |
EP3801519A4 (en) | 2022-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279188A (en) | Dosing and effect of c5a antagonist with anca-associated vasculitis | |
HK1249405A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
HK1252158A1 (en) | Masked anti-cd3 antibodies and methods of use | |
IL255336A0 (en) | Chimeric antigen receptors and methods of their use | |
IL262041A (en) | Chimeric receptors and methods of use thereof | |
IL272069A (en) | Dosage regimens of anti-lag-3 antibodies and uses thereof | |
HK1246355A1 (en) | Adeno-associated virus variants and methods of use thereof | |
IL288457A (en) | Humanized anti-human cd19 antibodies and methods of use | |
HK1259251A1 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
IL256086A (en) | Anti-her2 antibodies and methods of use | |
IL286208A (en) | Humanized influenza monoclonal antibodies and methods of use thereof | |
IL274045B1 (en) | Dantrolene prodrugs and methods of their use | |
IL265761A (en) | Terlipressin compositions and their methods of use | |
GB201720648D0 (en) | Aggregate pellets and methods of forming aggregate pellets | |
TWM488873U (en) | Thin and long cookie structure with a plurality of granules |